Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by TD Asset Management Inc

TD Asset Management Inc grew its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 23.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,010 shares of the company's stock after buying an additional 14,276 shares during the quarter. TD Asset Management Inc owned 0.15% of Soleno Therapeutics worth $5,288,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Sei Investments Co. increased its holdings in Soleno Therapeutics by 47.0% in the fourth quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after buying an additional 5,258 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Soleno Therapeutics in the 4th quarter worth approximately $193,000. Vanguard Group Inc. increased its holdings in shares of Soleno Therapeutics by 19.2% in the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after acquiring an additional 303,806 shares during the last quarter. Corebridge Financial Inc. increased its holdings in shares of Soleno Therapeutics by 2.9% in the 4th quarter. Corebridge Financial Inc. now owns 12,720 shares of the company's stock valued at $572,000 after acquiring an additional 357 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Soleno Therapeutics by 14.5% during the 4th quarter. Wellington Management Group LLP now owns 782,265 shares of the company's stock valued at $35,163,000 after acquiring an additional 99,095 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Robert W. Baird set a $121.00 price objective on shares of Soleno Therapeutics and gave the stock an "outperform" rating in a report on Friday, July 11th. Piper Sandler lifted their price target on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Cowen started coverage on shares of Soleno Therapeutics in a research note on Monday, June 23rd. They set a "buy" rating on the stock. Guggenheim raised their target price on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Soleno Therapeutics in a report on Tuesday, April 15th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $108.70.

Insider Transactions at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the completion of the transaction, the insider owned 13,206 shares of the company's stock, valued at approximately $1,092,928.56. This represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 6.40% of the company's stock.

Soleno Therapeutics Price Performance

NASDAQ SLNO opened at $86.00 on Friday. The company has a 50-day moving average price of $82.06 and a two-hundred day moving average price of $66.90. Soleno Therapeutics, Inc. has a 52 week low of $41.50 and a 52 week high of $90.32. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of -18.61 and a beta of -2.56. The company has a current ratio of 19.64, a quick ratio of 19.64 and a debt-to-equity ratio of 0.21.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.19. Analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.